The human papillomavirus, commonly known as HPV, has long been recognised as the most prevalent sexually transmitted infection worldwide.

It is notorious not only for causing genital warts but also for its association with multiple forms of cancer, most notably cervical cancer. In recent years, vaccination against HPV has become a public health priority, and now a robust body of evidence affirms that the vaccine is both highly effective and remarkably safe.

Recently, two influential reviews conducted by the respected Cochrane Review team in Britain have been published, reinforcing the case for routine HPV vaccination in adolescents. These reviews have drawn upon nearly 60 randomised controlled clinical trials, regarded as the gold standard in scientific research, involving a staggering 160,000 participants.

The findings are clear: the HPV vaccine significantly reduces infection rates, prevents precancerous cervical lesions and slashes the occurrence of genital warts.

But the evidence does not stop there. The reviews included a further 225 observational studies with data encompassing more than 132 million individuals globally. The magnitude of this research is difficult to overstate.

Together, these studies highlight a dramatic reduction in cervical cancer risk among girls who received the HPV vaccine before the age of 16—an astonishing 80% lower risk compared to their unvaccinated peers. These numbers are not mere statistics; they represent lives changed and futures preserved.

HPV itself is a family of viruses, several strains of which are causally linked to cancer. The Gardasil vaccine, produced by Merck and first approved in 2006, offers protection against nine cancer-causing strains of HPV.

Public health authorities such as the Centres for Disease Control and Prevention (CDC) in the United States recommend that both boys and girls receive the vaccine at ages 11 to 12, ideally before any sexual activity begins. The vaccine is also licensed for those aged 9 through 26, with eligibility extended up to age 45 in certain circumstances.

What makes these latest findings so compelling is not just their scale but their real-world impact. Recent surveillance data from Australia revealed that in 2021, there were no new cases of cervical cancer in women under 25—a milestone not seen since records began over four decades ago.

Similarly, Scotland’s public health agency reported that there were no diagnoses of cervical cancer among women fully vaccinated against HPV in their youth. These examples provide concrete evidence that the vaccine is transforming population health.

Critically, the Cochrane reviews addressed widespread concerns about vaccine safety. Myths abound on social media platforms, with claims linking the vaccine to infertility, chronic fatigue syndrome and even paralysis.

However, according to the reviews, thorough analysis found no credible evidence supporting these associations. Serious adverse events were rare and occurred at similar rates in both vaccinated groups and those who received a placebo.

The issue of vaccine safety has become especially prominent as debates surrounding immunisations gain traction internationally. In some circles, prominent anti-vaccine campaigners have publicly questioned the safety of the Gardasil vaccine and even profited from legal action against its manufacturer.

Yet the scientific consensus remains unwavering: leading experts stress that the evidence supporting both the effectiveness and safety of HPV vaccination is comprehensive and robust.

Despite these assurances, vaccination rates have stalled in some regions. Data from the CDC suggest that among American adolescents aged 13 to 17, HPV vaccination uptake flatlined from 2022 to 2024, with around 78% receiving at least one dose and only 63% completing the full course.

In contrast, uptake rates for other adolescent vaccines have surpassed 90%. Researchers attribute this shortfall to persistent safety concerns and social attitudes towards vaccinations targeting sexually transmitted infections.

Parental hesitancy remains a notable obstacle. Some families worry that immunising children against an STI could inadvertently encourage risky behaviour. Others believe their children are at low risk because they are not yet sexually active.

However, studies conducted at Harvard University and published in peer-reviewed journals have found no link between receiving the HPV vaccine and increased sexual risk-taking among youths.

Socioeconomic factors also play a role. A study published in The Lancet Regional Health indicated that white families and those with higher incomes in the United States were less likely to intend to vaccinate their children against HPV, often citing concerns about side effects or necessity.

The consequences of forgoing vaccination can be devastating on a personal level. Consider the story of a woman who declined the newly approved HPV vaccine as a teenager due to uncertainty and later developed cervical cancer in her twenties. Her journey through chemotherapy and radiation was harrowing. She suffered long-term side effects, including infertility and lymphedema—a condition resulting in painful fluid retention. Now a decade into remission, she dedicates her life to advocacy and urges others not to repeat her mistake. Does this make you think twice?

Globally, HPV causes an estimated 48,000 cases of cancer each year in the United States alone, including over 13,000 cases of cervical cancer. In Malaysia, cervical cancer is a significant health issue, ranking as the third most common cancer in women, primarily caused by HPV. Current estimates indicate that every year 1740 women are diagnosed with cervical cancer and 991 die from the disease in Malaysia.

The burden extends beyond women: men are also at risk of cancers caused by HPV—including anal, penile and cancers of the mouth and throat. While current evidence most conclusively demonstrates a reduction in cervical cancer following vaccination, it is expected that similar declines will emerge for these other cancers in time, given their longer latency periods.

The positive trend in cervical cancer incidence since the introduction of routine vaccination is striking. According to a study from the American Cancer Society published in 2023, cervical cancer rates among American women in their early twenties fell by 65% from 2012 to 2019—the first cohort to benefit from widespread HPV immunisation.

Public health officials underscore that early vaccination is essential for maximum protection. The immune response is strongest before exposure to HPV through sexual contact, making pre-adolescence the optimal window for immunisation.

The significance of these findings extends beyond individual countries or health systems. Cervical cancer remains a leading cause of death among women globally, particularly in low- and middle-income regions where screening programmes may be less accessible. Universal access to HPV vaccination has the potential to eliminate cervical cancer as a public health problem within a generation—an achievement once thought impossible.

Mounting evidence confirms that the HPV vaccine is safe and powerfully effective at preventing cervical cancer when administered before exposure to the virus. The reports from Britain’s Cochrane Review team provide clarity amidst public uncertainty and misinformation, offering reassurance that side effects are rare and largely indistinguishable from those associated with other vaccines or placebos.

The challenge now lies in boosting vaccination rates through education and outreach—dispelling myths, addressing parental concerns and ensuring equitable access across all communities.

With continued commitment from healthcare providers, policymakers and advocates worldwide, it is possible to consign HPV-related cancers to history.